| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health |
| Ongoing | 4 | 136 | Europe | Tablet, Xifaxan | Aleksander Krag, Dep. Gastroenterology Odense Universityhospital, Novo Nordisk fundation center for basic metabolic research | Liver fibrosis, Accumulation of scar tissue in the liver (fibrosis) may lead to the levelopment of liver cirrhosis. Liver cirrhosis is associated with a variety of complications and decreased survival., Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy |
|
|
| Terminated | 4 | 6 | US | Placebo, Rifaximin, XIFAXAN® Tablets | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 02/16 | 02/16 | | |
2016-002628-96: Does Rifaximin reduce the risk of infection for patients admitted to hospital with liver disease? |
|
|
| Ongoing | 4 | 268 | Europe | TARGAXAN, Film-coated tablet, TARGAXAN | Imperial College London, Norgine BV, Alfa Wassermann | Decompensated cirrhosis - liver disease, Liver disease, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
2018-004323-37: Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt: a multi-centre randomized, double blind, placebo controlled trial. The PEARL trial |
|
|
| Not yet recruiting | 4 | 238 | Europe | Xifaxan, Lactulose, Tablet, Syrup, Xifaxan, Lactulose | Academic Medical Centre, Academic Medical Centre, ZonMw, Norgine B.V. | post-TIPS Hepatic Encephalopathy (HE), Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt placement, Diseases [C] - Symptoms and general pathology [C23] | | | | |
2019-002116-10: Post-autorization study to compare the eficacy of the food supplement i3.1 and the antibiotic Rifaximin on SIBO (Small Intestinal Bacterial Overgrowth) reduction in patients suffering IBS (Irritable bowel syndrom). Estudio post-autorización para comparar la eficacia del complemento alimenticio i3.1 y el antibiótico Rifaximina en la reducción de SIBO (Sobrecrecimiento bacteriano en intestino delgado) en pacientes que padecen IBS (Síndrome intestino irritable). |
|
|
| Ongoing | 4 | 46 | Europe | SPIRAXIN, 62.250, Tablet, SPIRAXIN | AB-Biotics S.A., AB-Biotics S.A. | Irritable Bowel Syndrome (IBS) + Small Intestinal Bacterial Overgrowth (SIBO) Síndrome Intestino Irritable (SII) + Sobrecrecimiento bacteriano intestinal (SIBO), Irritable Bowel Syndrome (IBS) + Small Intestinal Bacterial Overgrowth (SIBO) Síndrome Intestino Irritable (SII) + Sobrecrecimiento bacteriano intestinal (SIBO), Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
NCT03818672: Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects |
|
|
| Terminated | 4 | 5 | US | Rifaximin | Bausch Health Americas, Inc. | Severe Hepatic Impairment | 02/20 | 02/20 | | |
PEARL, NCT04073290: Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose |
|
|
| Recruiting | 4 | 238 | Europe | Rifaximin 550 milligram Oral Tablet [XIFAXAN], TARGAXAN, Placebo oral tablet, Placebo, Lactulose 667 milligram/milliliter Oral Solution, Lactulose syrup | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, Leiden University Medical Center, Maastricht University Medical Center, Radboud University Medical Center, University Medical Center Groningen, Universitaire Ziekenhuizen Leuven, Norgine | Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension, Liver Diseases, Pathological Processes | 09/22 | 09/23 | | |
NCT06312683: Rifaximin for the Secondary Prevention of Recurrent Pouchitis |
|
|
| Recruiting | 4 | 16 | US | Rifaximin 550 MG Oral Tablet [XIFAXAN], Xifaxan | University of North Carolina, Chapel Hill, Bausch Health Americas, Inc. | Pouchitis | 07/26 | 07/26 | | |
2017-000488-34: Role of rifaximin in decreasing the circulating levels of endotoxin in patients with cirrhosis Ruolo della rifaximina per ridurre gli alti livelli sanguigni di endotossina nei pazienti affetti da cirrosi epatica |
|
|
| Not yet recruiting | 3 | 40 | Europe | RIFAXIMINA, n.a, Film-coated tablet, TIXTELLER - 550 MG COMPRESSE RIVESTITE CON FILM 14 COMPRESSE IN BLISTER PVC/PE/PVDC/AL | UMBERTO I - POLICLINICO DI ROMA, ALFA WASSERMANN S.p.A | PATIENTS WITH CIRRHOSIS CHILD PUGH B or C Classes PAZIENTI AFFETTI DA CIRROSI EPATICA CLASSE CHILD-PUGH B or C, ADVANCED CHRONIC LIVER DISEASE MALATTIA EPATICA CRONICA AVANZATA, Diseases [C] - Digestive System Diseases [C06] | | | | |
2018-001891-39: Antibiotic treatment (Rifaxamin) of a chronic inflammatory diarrhoeal disease (Collagenous Colitis) |
|
|
| Ongoing | 3 | 48 | Europe | Xifaxan, Coated tablet, Xifaxan | XiCoCo study group, Norgine, Forskningsfonden Hospitalenhed Midt | Collagenous Colitis, Collagenous colitis is a chronic inflammatory diarrhoeal disease. The hypothesis is that supplemental treatment wit Xifaxan can lower the risk of relapse after discontinuation of standard treatment., Diseases [C] - Digestive System Diseases [C06] | | | | |
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites |
|
|
| Completed | 3 | 160 | Europe | Rifaximin, Placebo | Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA | Cirrhosis, Ascites, Peritonitis | 06/22 | 03/23 | | |
RED-C-3131, NCT05071716: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis |
|
|
| Active, not recruiting | 3 | 524 | Canada, US, RoW | Rifaximin SSD, Placebo | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 09/25 | 09/25 | | |
RED-C-3132, NCT05297448: Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis |
|
|
| Active, not recruiting | 3 | 466 | Europe, Canada, US, RoW | Rifaximin SSD, Placebo | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 01/26 | 01/26 | | |
NCT04118699: Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial |
|
|
| Active, not recruiting | 2 | 12 | Japan | Rifaximin oral tablet, L-105, Placebo oral tablet | Yokohama City University, ASKA Pharmaceutical Co., Ltd. | Chronic Intestinal Pseudo-obstruction | 11/21 | 01/22 | | |
| Not yet recruiting | 2 | 60 | Europe | Film-coated tablet, TARGAXAN | KU Leuven, European Research Council (ERC) | Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test whether rifaximin administration has an effect on sensitivity to psychosocial stress, fear learning, and mood, Experimental study with healthy participants from the general population. We will test if rifaximin administration has an effect on sensitivity to psychosocial stress, fear learning, and mood., Psychiatry and Psychology [F] - Psychological processes [F02] | | | | |
NCT05098028: Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease |
|
|
| Completed | 2 | 44 | Canada, US, RoW | Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER, High Dose Rifaximin DER, Placebo | Bausch Health Americas, Inc. | Sickle Cell Disease | 09/23 | 09/23 | | |
NCT05502913: Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Antibiotics, Rifaximin, FMT (Fecal Microbiota Transplantation) | Soroka University Medical Center, Biotax Labs LTD, Israel Cancer Association | Metastatic Lung Cancer | 06/25 | 06/28 | | |
| Active, not recruiting | 1/2 | 60 | Europe | Fecal Microbiota Transfer provided by Human Biome Institute, Pretreatment with rifaximin 3x 400 mg PO for 7 days, Assessment of levodopa/benserazide 100+25 mg tablet absorption before and 90 days after intervention: 20,40, 60, 90, 120, 150, 180 and 240 min since intervention- Area under the curve (AUC), Cmax, Assessment in clinical scales | Medical University of Warsaw, Human Biome Institute S.A. | Parkinson Disease | 10/23 | 12/24 | | |
| Suspended | 1/2 | 86 | US | Rifaximin, Placebo | University of California, San Francisco, Nova Southeastern University, Gateway Institute for Brain Research | Parkinson Disease | 06/25 | 06/25 | | |
NCT06298409: Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® |
|
|
| Recruiting | 1 | 34 | US | CapScan collection capsule | Envivo Bio Inc | Small Intestinal Bacterial Overgrowth | 06/25 | 07/25 | | |
NCT04910815: Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting. |
|
|
| Recruiting | N/A | 150 | RoW | Atmo Gas Capsule, Glucose Breath Test, Fructoolifosaccharides (FOS) Breath Test, Jejunal Aspiration and culture, Rifaximin, Placebo | Atmo Biosciences Pty Ltd | Small Intestinal Bacterial Overgrowth | 06/24 | 08/24 | | |